Investigating Genetic Status in Patients Presenting to Clinic

Alzheimer Dementia (AD) Clinical Trial

Official title:

Investigating Genetic Status in Patients Presenting to Clinic

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05911932
• Other study ID #: 121760
• Status: Recruiting
• Start date: October 20, 2023
• Est. completion date: August 2043

Study information

• Verified date: December 2023
• Source: Lawson Health Research Institute
• Contact: Sarah Jesso
• Phone: 519-646-6000
• Email: cognitiveneurology[@]sjhc.london.on.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The causes of neurodegenerative dementias such as Frontotemporal Dementia, Lewy Body Disease and Alzheimer's disease are still largely unknown. While the contribution of some genetic mutations and polymorphisms is associated with autosomal dominant patterns of inheritance of these dementias, in many cases, the specific causative mutation in these families is not yet identified. Further, in many patients, polygenic risk is thought to give rise to pathophysiologic changes, but which specific genes affect risk are largely yet unknown. By examining genotypes in patients that present to our Cognitive Neurology and Alzheimer's Research Clinic with suspected or confirmed neurodegenerative dementia, or have a history of a familial dementia, we aim to help identify and characterize genetic mutations or polymorphisms that give rise to neurodegenerative diseases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: August 2043
• Est. primary completion date: August 2038
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Persons presenting to the cognitive clinic with a neurodegenerative disorder (for example, AD, FTD, LBD, ALSP, and related conditions);
• Biological family members of someone diagnosed with a neurodegenerative disorder, presenting to clinic;
• Age 18+ years old;
• Consenting to a blood draw.

Exclusion Criteria:

• Persons declining / unwilling / not able to have a blood draw.

Related Conditions & MeSH terms

• Alzheimer Dementia (AD)
• Alzheimer Disease
• Aphasia, Primary Progressive
• Dementia
• Frontotemporal Dementia
• Lewy Body Dementia (LBD)
• Lewy Body Disease
• Pick Disease of the Brain

Intervention

Other:
• Biosample collection.
Blood draw.

Locations

Country	Name	City	State
Canada	Parkwood Institute	London	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Lawson Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood draw for genetic status or polymorphism result.	The blood draw is taken at the time of the clinic visit. Up to 30ml will be collected by standard venipuncture.	A one-time visit, taking the participant approximately 20 minutes total for all study procedures.
Secondary	Demographic information.	Demographic information will be collected at the time of the clinic visit.	A one-time visit, taking the participant approximately 20 minutes total for all study procedures.
Secondary	Medical history/Clinical diagnoses.	Will be obtained via chart review when available. This information is collected already as part of the patient's standard care.	Typically within 1 month of the clinic visit, taking approximately 5 minutes.
Secondary	Pathological diagnoses.	Will be obtained via chart review when available. This information is collected already as part of the patient's standard care.	Typically within 1 month of the clinic visit, taking approximately 5 minutes.